ANIK Stock Overview
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally.
No risks detected for ANIK from our risk checks.
Anika Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$22.51|
|52 Week High||US$45.81|
|52 Week Low||US$19.95|
|1 Month Change||2.09%|
|3 Month Change||-10.35%|
|1 Year Change||-48.00%|
|3 Year Change||-45.68%|
|5 Year Change||-54.82%|
|Change since IPO||543.14%|
Recent News & Updates
|ANIK||US Biotechs||US Market|
Return vs Industry: ANIK underperformed the US Biotechs industry which returned -26.1% over the past year.
Return vs Market: ANIK underperformed the US Market which returned -20.4% over the past year.
|ANIK Average Weekly Movement||6.0%|
|Biotechs Industry Average Movement||13.1%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: ANIK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: ANIK's weekly volatility (6%) has been stable over the past year.
About the Company
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products.
Anika Therapeutics Fundamentals Summary
|ANIK fundamental statistics|
Is ANIK overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ANIK income statement (TTM)|
|Cost of Revenue||US$60.09m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.11|
|Net Profit Margin||-1.09%|
How did ANIK perform over the long term?See historical performance and comparison
Is ANIK undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ANIK?
Other financial metrics that can be useful for relative valuation.
|What is ANIK's n/a Ratio?|
Price to Sales Ratio vs Peers
How does ANIK's PS Ratio compare to its peers?
|ANIK PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
GRNA GreenLight Biosciences Holdings
GRCL Gracell Biotechnologies
ANIK Anika Therapeutics
Price-To-Sales vs Peers: ANIK is good value based on its Price-To-Sales Ratio (2.2x) compared to the peer average (1801x).
Price to Earnings Ratio vs Industry
How does ANIK's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: ANIK is good value based on its Price-To-Sales Ratio (2.2x) compared to the US Biotechs industry average (13.4x)
Price to Sales Ratio vs Fair Ratio
What is ANIK's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||2.2x|
|Fair PS Ratio||2.1x|
Price-To-Sales vs Fair Ratio: ANIK is expensive based on its Price-To-Sales Ratio (2.2x) compared to the estimated Fair Price-To-Sales Ratio (2.1x).
Share Price vs Fair Value
What is the Fair Price of ANIK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ANIK ($22.51) is trading above our estimate of fair value ($5.36)
Significantly Below Fair Value: ANIK is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ANIK's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Anika Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ANIK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: ANIK is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ANIK is expected to become profitable in the next 3 years.
Revenue vs Market: ANIK's revenue (7.9% per year) is forecast to grow slower than the US market (8.3% per year).
High Growth Revenue: ANIK's revenue (7.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ANIK's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Anika Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ANIK is currently unprofitable.
Growing Profit Margin: ANIK is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ANIK is unprofitable, and losses have increased over the past 5 years at a rate of 45% per year.
Accelerating Growth: Unable to compare ANIK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ANIK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: ANIK has a negative Return on Equity (-0.57%), as it is currently unprofitable.
Discover strong past performing companies
How is Anika Therapeutics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: ANIK's short term assets ($165.3M) exceed its short term liabilities ($27.0M).
Long Term Liabilities: ANIK's short term assets ($165.3M) exceed its long term liabilities ($29.5M).
Debt to Equity History and Analysis
Debt Level: ANIK is debt free.
Reducing Debt: ANIK had no debt 5 years ago.
Debt Coverage: ANIK has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: ANIK has no debt, therefore coverage of interest payments is not a concern.
Discover healthy companies
What is Anika Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ANIK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ANIK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ANIK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ANIK's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ANIK has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Cheryl Blanchard (57 yo)
Dr. Cheryl Renee Blanchard, Ph.D. serves as the President & Chief Executive Officer of Anika Therapeutics, Inc. since April 26, 2020. She serves as Director of Vigil Neuroscience, Inc. Since November 2020....
CEO Compensation Analysis
Compensation vs Market: Cheryl's total compensation ($USD4.20M) is above average for companies of similar size in the US market ($USD2.81M).
Compensation vs Earnings: Cheryl's compensation has been consistent with company performance over the past year.
Experienced Management: ANIK's management team is considered experienced (2.1 years average tenure).
Experienced Board: ANIK's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ANIK insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Anika Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Anika Therapeutics, Inc.
- Ticker: ANIK
- Exchange: NasdaqGS
- Founded: 1983
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$327.382m
- Shares outstanding: 14.54m
- Website: https://www.anikatherapeutics.com
Number of Employees
- Anika Therapeutics, Inc.
- 32 Wiggins Avenue
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/29 00:00|
|End of Day Share Price||2022/06/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.